540359 PARMAX

Parmax Pharma Share Price

₹40.60 -2.35 (-5.47%)

26 Mar, 2025 17:38

SIP TrendupStart SIP in PARMAX

Start SIP

Performance

  • Low
  • ₹39
  • High
  • ₹41
  • 52 Week Low
  • ₹25
  • 52 Week High
  • ₹54
  • Open Price₹39
  • Previous Close₹43
  • Volume195

Investment Returns

  • Over 1 Month -5.58%
  • Over 3 Month -1.79%
  • Over 6 Month -17.48%
  • Over 1 Year + 35.7%
SIP Lightning

Smart Investing Starts Here Start SIP with Parmax Pharma for Steady Growth!

Invest Now

Parmax Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -7.4
  • PEG Ratio
  • -0.1
  • Market Cap Cr
  • 15
  • P/B Ratio
  • -23.8
  • Average True Range
  • 2.75
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.04
  • RSI
  • 51.55
  • MFI
  • 56.04

Parmax Pharma Financials

Parmax Pharma Technicals

EMA & SMA

Current Price
₹40.60
-2.35 (-5.47%)
pointer
  • stock-down_img
  • Bearish Moving Average 14
  • stock-up_img
  • Bullish Moving Average 2
  • 20 Day
  • ₹42.38
  • 50 Day
  • ₹42.43
  • 100 Day
  • ₹42.28
  • 200 Day
  • ₹40.51

Resistance and Support

41.68 Pivot Speed
  • R3 48.02
  • R2 45.48
  • R1 44.22
  • S1 40.42
  • S2 37.88
  • S3 36.62

What's your outlook on Parmax Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Parmax Pharma has an operating revenue of Rs. 27.64 Cr. on a trailing 12-month basis. An annual revenue de-growth of -28% needs improvement, Pre-tax margin of -51% needs improvement, ROE of -8146% is poor and needs improvement. The company has a high debt to equity of 8326%, which can be a reason to worry. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 49 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has some relative strength and buyer demand but we want to see further fundamental performance to qualify as a growth stock. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Parmax Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-14 Quarterly Results
2024-11-14 Quarterly Results
2024-08-14 Quarterly Results
2024-05-30 Audited Results (Revised)
2024-02-14 Quarterly Results

Parmax Pharma F&O

Parmax Pharma Shareholding Pattern

30.8%
63.11%
6.09%

About Parmax Pharma

  • NSE Symbol
  • PARMAX
  • BSE Symbol
  • 540359
  • Managing Director
  • Dr. Umang Alkesh Gosalia
  • ISIN
  • INE240T01014

Similar Stocks to Parmax Pharma

Parmax Pharma FAQs

Parmax Pharma share price is ₹40 As on 26 March, 2025 | 17:24

The Market Cap of Parmax Pharma is ₹15.2 Cr As on 26 March, 2025 | 17:24

The P/E ratio of Parmax Pharma is -7.4 As on 26 March, 2025 | 17:24

The PB ratio of Parmax Pharma is -23.8 As on 26 March, 2025 | 17:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23